SUN-282 Demographics, Clinical Characteristics, and Hospital Settings of Insulinoma Patients: Insights from a National Inpatient Sample

Abstract Disclosure: M. Colorado: None. S. Sangam: None. A. Sajan: None. Insulinomas are hormone-producing pancreatic neuroendocrine tumors with an annual incidence of 1 to 4 cases per million. Current data on the demographics and clinical characteristics of patients with insulinomas in the United States is limited, as is information regarding the hospital settings where these cases are managed. Our study aims to clarify and provide insight into this information. A cross-sectional retrospective study was performed using data from the National Inpatient Sample (2016 to 2021). The International Statistical Classification of Diseases (ICD-10) coding system was used to identify both primary and secondary diagnoses. The study included all adult patients (aged over 18 years) admitted with a primary diagnosis of insulinoma. We compared demographic information, baseline clinical characteristics, and hospital characteristics among patients with insulinoma. Statistical analyses were performed using the survey procedures function in STATA v.17. A total of 7,245 patients with a primary diagnosis of insulinoma were included in the study during the specified period. The mean age of the study population was 60.6 years, with an almost equal prevalence among females and males (50.24% vs. 49.76%). The majority of patients identified as White, making up 68% of the population. The study revealed a relatively balanced distribution of income, with a slight increase in the proportion of individuals in the highest income quartile (27%). Most patients received treatment at urban teaching hospitals compared to non-teaching and rural hospitals (83.64% vs. 16.36%). The distribution of hospitals by region was fairly even, with the South accounting for the largest portion (37.2%), followed by the Midwest (22.08%), Northeast (20.98%), and West (19.74%). Comorbidities included congestive heart failure (12%), renal disease (17%), mild liver disease (6%), severe liver disease (5%), and diabetes mellitus (24%, with 11% experiencing diabetes with complications). These findings provide valuable insights into the demographics, hospital settings, and comorbidity profiles of insulinoma patients in the United States. However, limitations must be taken into consideration, such as potential coding errors in administrative data and the focus exclusively on hospitalized patients. While these results offer important information, further prospective studies are necessary to validate and expand on these findings. Presentation: Sunday, July 13, 2025